August 25th 2025
Answering all the questions ophthalmologists may have ahead of the EURETINA Congress in Paris, France
Faricimab approved for treatment of nAMD, DMO by European Commission
September 19th 2022Roche’s treatment of faricimab is the first and only FDA-approved medicine targeting two distinct pathways, angiopoietin (Ang)-2 and vascular endothelial growth factor (VEGF)-A, that often cause retinal diseases that may cause visual loss.
Positive interim data in Phase 2 BEHOLD trial investigating UBX1325 in DMO patients
September 10th 202212-week interim results of BEHOLD, a proof-of-concept Phase 2a study investigating the candidate UBX1325, provides a positive outlook for a novel senolytic approach for previously-treated patients with diabetic macular oedema.
Fluid monitor utilises AI to identify, localise and quantify retinal fluid
September 7th 2022Eyecare specialists benefit from being able to monitor their patients long term for optimised and personalised treatment regimens, as well as having access to a more efficient workflow and one which enables them to see more patients.
Multicentre Phase 3 clinical trial using AI in nAMD identifies, measures fluid volumes in real time
September 6th 2022According to Dr Gregor S. Reiter, the results from the multicentre Phase 3 clinical trial demonstrated that fluid volumes in patients with nAMD can be precisely identified, localised and measured in real-time using artificial intelligence.
First analysis of gene therapy for RPE65 inherited retinal dystrophies shows good safety, efficacy
September 3rd 2022At the 1-month evaluation, the full-field stimulus threshold had median decrease of -33.2 decibels (dB) (-33.7; -19.8) dB, which remained stable until the last assessment. Visual fields and visual acuity did not change significantly.